Denali Therapeutics Inc. (DNLI) P/S ratio

P/S ratio · fiscal 2023
8.9×

The P/S ratio of Denali Therapeutics Inc. (DNLI) was 8.9× at the end of fiscal 2023 (December 31, 2023). That is 72.3% lower than the 32.2× of fiscal 2022. Figures as of 18 Nov 2026, 06:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio, fiscal 2023
8.9×
Change on fiscal 2022
−72.3%
Highest on record
111.4×fiscal 2021
Lowest on record
8.9×fiscal 2023
Fiscal years on record
62018–2023

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Denali Therapeutics Inc. P/S ratio, in more detail

Across the 6 fiscal year-ends on record (2018–2023), the highest was 111.4× in fiscal 2021 and the lowest 8.9× in fiscal 2023.

History · 6 fiscal years

P/S ratio at each fiscal year-end

Denali Therapeutics Inc. P/S ratio, year by year

Denali Therapeutics Inc. (DNLI) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
2025——$16.51—
2024——$20.38—
20238.9× 72.3% down$21.46$2.41
202232.2× 71.1% down$27.81$0.86
2021111.4× 296.0% up$44.60$0.40
202028.1× 55.5% down$83.76$2.98
201963.3× 326.9% up$17.42$0.28
201814.8×—$20.66$1.39
2017——$15.64—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on DNLI

Denali Therapeutics Inc., figure by figure

Denali Therapeutics Inc. (DNLI) overview: price, valuation and scorecard

Denali Therapeutics Inc. P/S ratio: questions and answers

What is Denali Therapeutics Inc.'s P/S ratio?

The P/S ratio of Denali Therapeutics Inc. (DNLI) was 8.9× at the end of fiscal 2023 (December 31, 2023). That is 72.3% lower than the 32.2× of fiscal 2022.

What are the highest and lowest P/S ratio figures on record for Denali Therapeutics Inc.?

Across the 6 fiscal year-ends on record (2018–2023), the highest was 111.4× in fiscal 2021 and the lowest 8.9× in fiscal 2023.

How is Denali Therapeutics Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Denali Therapeutics Inc. (DNLI) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/DNLI/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.